The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

strekin.com

Founded Year

2014

Stage

Series A | Alive

Total Raised

$13.14M

Last Raised

$2.84M | 3 yrs ago

About Strekin

Strekin focuses on repurposing existing drugs by discovering new mechanisms of action.

Strekin Headquarter Location

Technologiepark Basel Hochbergerstrasse 60C

Basel, 4057,

Switzerland

+41 616332971

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Strekin

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Strekin is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Strekin Patents

Strekin has filed 1 patent.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Excipients
  • Liberal democracies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/3/2018

Diseases of the eye and adnexa, Excipients, Liberal democracies, Life sciences industry, Ophthalmology

Application

Application Date

4/3/2018

Grant Date

Title

Related Topics

Diseases of the eye and adnexa, Excipients, Liberal democracies, Life sciences industry, Ophthalmology

Status

Application

Latest Strekin News

Strekin AG completes patient recruitment in RESTORE Ph3 of STR001

Sep 16, 2019

15 September 2019 | News An international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event Photo credit: dmgpr Strekin AG, a biopharmaceutical company focused on treatments for hearing loss, on 12 Sep 2019, announced that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event. RESTORE is evaluating the ability of STR001 given by intratympanic injection with and without 3-month oral follow-up with STR001 tablets to restore hearing in SSNHL. RESTORE has completed enrollment of the target of 165 patients at approximately 25 clinical centers across 5 European countries. STR001 has been very well tolerated and topline results from RESTORE are anticipated to be released in early 2020. "We are pleased to have completed patient enrollment in the Phase 3 RESTORE clinical trial which is designed to evaluate the ability of STR001 activity to reverse hearing loss following a SSNHL event," remarked Alexander Bausch, Chief Executive Officer of Strekin. "The RESTORE trial tests the ability of STR001 to address a clear unmet medical need in patients who have suffered severe hearing loss that may lead to a debilitating life-long handicap. If successful, the data provided by RESTORE, along with the orphan drug status of STR001 for SSNHL in the EU, may enable STR001 to become the first approved treatment for SSNHL patients."

Strekin Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Strekin Rank

  • When was Strekin founded?

    Strekin was founded in 2014.

  • Where is Strekin's headquarters?

    Strekin's headquarters is located at Technologiepark Basel, Basel.

  • What is Strekin's latest funding round?

    Strekin's latest funding round is Series A.

  • How much did Strekin raise?

    Strekin raised a total of $13.14M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.